Precision medicine in lymphoid malignancies
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Identification of high-risk disease using molecular profiling by Mymap
Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design
What is the rationale for novel combination therapies?
Niels van de Donk